Dissecting the Anti-Glioma Mechanism of Shenqi Fuzheng Injection via SRC/PI3K/AKT: Network Pharmacology and Experimental Insights

Study Background and Research Question

Gliomas, accounting for up to half of all primary brain tumors, remain a formidable clinical challenge due to their aggressive proliferation, diffuse infiltration, and poor patient prognosis despite standard interventions such as surgery, radiotherapy, and chemotherapy. Median survival for glioma patients typically falls below 17 months, highlighting the urgent need for new mechanistic insights and therapeutic strategies. Traditional Chinese medicines, including Shenqi Fuzheng injection (SFI)—a clinical adjuvant composed of Codonopsis pilosula and Astragalus membranaceus—have shown promise in cancer adjunctive therapy, but their anti-glioma mechanisms remain poorly defined. The current study sought to clarify SFI's molecular mechanism against glioma proliferation and migration, focusing on potential signaling pathways implicated in tumor progression (reference study).

Key Innovation from the Reference Study

The central innovation of this research lies in its integration of network pharmacology with rigorous experimental validation to map the multi-target effects of SFI in glioma models. Rather than focusing on single molecular endpoints, the authors employed computational target prediction, pathway enrichment, and in vivo/in vitro assays to systematically identify and validate the SRC/PI3K/AKT pathway as a key mediator of SFI's anti-glioma activity. This approach offers a holistic view of how complex botanical formulations exert anti-tumor effects through coordinated modulation of signaling networks, particularly those governing cell proliferation, migration, and survival.

Methods and Experimental Design Insights

The study began with an extensive network pharmacology analysis. Researchers compiled known bioactive components of SFI and predicted their protein targets using established databases. In parallel, glioma-associated targets were aggregated from literature and bioinformatics sources. By intersecting these datasets, they identified 79 overlapping targets potentially relevant to both SFI activity and glioma pathology. Pathway enrichment analysis highlighted the SRC/PI3K/AKT axis as a probable mechanistic node.

Experimental validation proceeded in two directions:

• In vitro assays: Human glioma cell lines (U87, T98G) were used to assess SFI's impact on cell proliferation (CCK-8, EdU, plate cloning), migration (scratch and Transwell assays), cell cycle progression (flow cytometry), and epithelial-mesenchymal transition (EMT) marker expression (immunofluorescence, Western blot).
• In vivo confirmation: A subcutaneous glioma model in C57BL/6 mice (GL261 cell line) evaluated tumor growth, with histological and immunohistochemical analyses to assess the impact of SFI on tumor size and molecular markers.

Core Findings and Why They Matter

Results demonstrated that SFI significantly inhibits glioma cell proliferation by arresting cells in S-phase and suppressing migration capabilities. SFI also downregulated EMT markers, suggesting a blockade of key steps in metastatic dissemination. In vivo, SFI treatment led to a marked reduction in tumor growth. Mechanistically, both network analysis and experimental data converged on the SRC/PI3K/AKT signaling pathway as a central mediator of these effects, with SFI downregulating pathway components at the protein level. The identification of the SRC/PI3K/AKT axis as a convergence point for SFI's action is particularly noteworthy, as this pathway is frequently implicated in oncogenic signaling, angiogenesis, and resistance mechanisms in glioma and other tumors (reference study).

These findings are especially relevant for researchers seeking to modulate tumor angiogenesis and migration, as the SRC/PI3K/AKT pathway interfaces with VEGF-driven angiogenic signaling cascades. The data align with recent research highlighting the anti-angiogenic and anti-metastatic potential of botanical agents in preclinical models (internal article).

Comparison with Existing Internal Articles

Internal resources have previously discussed the anti-tumor potential of SFI and its impact on key signaling networks. For instance, the article "Network Pharmacology Uncovers SFI's Anti-Glioma Mechanisms via SRC/PI3K/AKT" provides an overview of the same study framework, confirming that network pharmacology can clarify the multi-target effects of SFI and its inhibition of the SRC/PI3K/AKT axis. Meanwhile, "AAL-993: Precision VEGF Receptor Inhibitor for Tumor Angiogenesis" explores how targeted small molecules such as AAL-993 can dissect and inhibit VEGF-mediated angiogenesis, a process functionally linked to the pathways modulated by SFI. The convergence of these approaches—botanical network pharmacology and precision kinase inhibition—underscores the value of integrated preclinical strategies in tumor angiogenesis research.

Limitations and Transferability

While the combination of computational and experimental methods provides compelling mechanistic evidence, several caveats remain. The complexity of SFI's botanical composition introduces variability in active compound concentrations, which could affect reproducibility. Furthermore, results from in vitro and subcutaneous mouse models may not fully recapitulate the tumor microenvironment or clinical heterogeneity seen in patients with glioma. The study also does not address possible off-target or systemic effects of SFI, and the precise contribution of individual SFI components requires further dissection. Translation to clinical application will necessitate more detailed pharmacokinetic, pharmacodynamic, and safety studies.

Research Support Resources

For researchers aiming to further interrogate angiogenic and proliferative signaling in glioma or related tumor models, access to well-characterized, selective inhibitors is crucial. AAL-993 (SKU C3730) is a potent and selective VEGF receptor inhibitor targeting VEGFR-1, VEGFR-2, and VEGFR-3, and can be leveraged to delineate the contribution of VEGF-driven angiogenesis in preclinical tumor studies. The inhibitor's robust selectivity and in vivo efficacy make it a valuable tool for dissecting the interplay between angiogenic and oncogenic pathways highlighted in network pharmacology studies such as this. Additional details on AAL-993, including its protocol parameters and storage recommendations, are available from APExBIO.

Protocol Parameters

• In vitro VEGFR inhibition: Use AAL-993 at concentrations determined by target IC50s (e.g., 23 nM for VEGFR-2) for kinase assays or cellular proliferation/migration studies.
• In vivo tumor angiogenesis modeling: Typical effective doses begin at 7 mg/kg (ED50 in mouse melanoma models), with administration protocols tailored to specific tumor models and experimental endpoints.
• Solubility and storage: Prepare stock solutions in DMSO or ethanol; store at -20°C and use freshly prepared aliquots for optimal activity.

Utilizing pathway-targeted inhibitors like AAL-993 alongside network pharmacology approaches can yield deeper insights into the overlapping mechanisms of anti-angiogenic compounds, botanical formulations, and tumor suppressive strategies.